SPDR Advertisement SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator binks, Seel
Search This Board:
Last Post: 2/27/2015 11:03:34 PM - Followers: 126 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for IDRA
IDRA News: Idera to Present at Two Upcoming Investor Healthcare Conferences 02/23/2015 12:00:00 PM
IDRA News: Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock 02/19/2015 03:21:36 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 02/17/2015 07:40:21 AM
IDRA News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 02/13/2015 05:22:07 PM
IDRA News: Current Report Filing (8-k) 02/13/2015 08:42:27 AM
PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1599   Yup. I jumped back in on the offering Randolph Duke 02/27/15 11:03:34 PM
#1598   Some rather large closing trades, almost 1.5 million CHM_760 02/27/15 04:09:15 PM
#1597   188,000 share dump right at the end. Citrati 02/27/15 04:07:58 PM
#1596   not so much today binks 02/27/15 04:03:14 PM
#1595   Good day for IDRA.... Good to see! GLA TheWatcher51 02/26/15 09:14:51 PM
#1594   Yeah and we didn't fade into close binks 02/26/15 04:38:57 PM
#1593   A nice GREEN day AGAIN.... :-) Citrati 02/26/15 04:27:51 PM
#1592   I hope you're right... I still have a CHM_760 02/26/15 02:33:28 PM
#1591   IDRA has lots of room to run. noretreat 02/26/15 02:20:33 PM
#1590   Trying really hard to work on a close Citrati 02/26/15 10:13:35 AM
#1589   Hmmm Cbdpotential 02/25/15 01:14:02 PM
#1588   Looks like this ceiling is going to take Citrati 02/24/15 11:49:31 AM
#1587   Continuing the march to $5. Citrati 02/23/15 10:33:15 AM
#1586   Been here for 8 mos now and still Miracleman 1 02/22/15 01:30:21 PM
#1585   Me too. I'm holding tight! TheHound 02/20/15 10:22:12 PM
#1584   Enjoy your greens this weekend!! :-) Citrati 02/20/15 04:23:39 PM
#1583   I do C! And this week was pure Seel 02/20/15 04:19:59 PM
#1582   Tru Dat. Be Green Citrati 02/20/15 03:29:33 PM
#1581   We will post more when we break last binchey 02/20/15 02:58:55 PM
#1580   No posts today when we continue printing GREEN? Citrati 02/20/15 12:35:56 PM
#1579   Douglas W. House, SA News Ed... Citrati 02/19/15 04:06:25 PM
#1578   I think we could see 8-10 by this binks 02/17/15 06:23:40 PM
#1577   Soon, we will have upgrades and brand new binchey 02/17/15 01:58:17 PM
#1576   all but a given. looking good C. TheHound 02/17/15 01:11:08 PM
#1575   Totally agree NR. IDRA has the potential and Citrati 02/17/15 11:18:27 AM
#1574   This has a long way to run up. noretreat 02/17/15 11:06:28 AM
#1573   That is nice news. This one kinda dwarfs Citrati 02/17/15 10:28:34 AM
#1572   Late insider buy of 400,000+ shares 3.75 KingDMC 02/17/15 09:51:18 AM
#1571   Yep, group warm fuzzies are nice. Citrati 02/15/15 12:24:09 AM
#1570   I love it when I see No Retreat MrW 02/14/15 10:47:17 PM
#1569   The intellectual challenge is addictive, esp for those Seel 02/13/15 03:25:58 PM
#1568   When J.D. Rockefeller was asked "How much money noretreat 02/13/15 02:06:13 PM
#1567   Well - you will have no retirement worries, Seel 02/13/15 02:01:01 PM
#1566   That was only 2 years ago! I noretreat 02/13/15 01:58:53 PM
#1565   Wow! Under a buck. That's incredible! Seel 02/13/15 01:53:19 PM
#1564   Very well done. Congrats. Citrati 02/13/15 01:49:59 PM
#1563   I'm in just over what Baker is paying...not noretreat 02/13/15 01:47:25 PM
#1562   In the offering filing it states Baker will Citrati 02/13/15 01:42:47 PM
#1561   I have had a lot of "luck" buying noretreat 02/13/15 01:38:15 PM
#1560   Adding a good stock at the sight of Citrati 02/13/15 10:42:21 AM
#1559   Ouch. The pain! Stop the pain. TheHound 02/13/15 10:27:31 AM
#1558   added at 3.93 this morning noretreat 02/13/15 09:34:13 AM
#1557   My guess is we test lower, maybe even Citrati 02/13/15 09:12:10 AM
#1556   Looking for a bounce off of the offering KingDMC 02/13/15 08:40:45 AM
#1555   Idera Pharmaceuticals Announces Pricing of Public Offering of KingDMC 02/13/15 08:40:27 AM
#1554   Me too. That is often a signal to Citrati 02/11/15 06:36:51 PM
#1553   I hope nobody sold on the offering news... binks 02/11/15 05:03:38 PM
#1552   Run baby run! TheHound 02/11/15 11:12:25 AM
#1551   Baker Bro. taking up to $20million of the Citrati 02/11/15 10:34:23 AM
#1550   Not a bummer. You are correct depending Citrati 02/10/15 08:45:42 PM
PostSubject